HLB Genex Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 78

Employees

  • Stock Symbol
  • 187420

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.31
  • (As of Monday Closing)

HLB Genex General Information

Description

HLB Genex Inc, formerly GenoFocus Inc is a high-throughput protein evolution company engaged in the development, manufacture, and distribution of enzymes like Lactazyme, chitizyme, and lipase. It develops enzyme solutions for specialty food, eco-friendly processes, biopharmaceuticals, cosmeceuticals, and agriculture.

Contact Information

Formerly Known As
Geno Focus
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 65 Techno 1-ro, Yuseong-gu
  • Daejeon, 34014
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 65 Techno 1-ro, Yuseong-gu
  • Daejeon, 34014
  • South Korea
+82

HLB Genex Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HLB Genex Stock Performance

As of 16-Nov-2026, HLB Genex’s stock price is $1.31. Its current market cap is $42.9M with 32.6M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.31 $1.37 $0.88 - $2.42 $42.9M 32.6M 375K $0.19

HLB Genex Financials Summary

As of 30-Sep-2026, HLB Genex has a trailing 12-month revenue of $32.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 63,409 62,066 97,727 105,446
Revenue 32,354 30,475 25,967 20,657
EBITDA 14,047 26,727 (6,359) 6,324
Net Income 5,415 15,874 (13,799) (2,256)
Total Assets 85,423 94,325 99,297 75,940
Total Debt 23,209 30,225 30,261 48,377
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HLB Genex Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore HLB Genex‘s full profile, request access.

Request a free trial

HLB Genex Patents

HLB Genex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025095595-A1 Superoxide dismutase and uses thereof for preventing or treating kidney injury Inactive 30-Oct-2023
WO-2024049280-A1 Bacillus species strain expressing superoxide dismutase, bacillus species strain spore and/or superoxide dismutase, and use thereof for preventing or treating of fibrotic disease Inactive 01-Sep-2022
WO-2024049280-A9 Bacillus species strain expressing superoxide dismutase, bacillus species strain spore and/or superoxide dismutase, and use thereof for preventing or treating of fibrotic disease Inactive 01-Sep-2022
JP-2025517375-A Superoxide dismutase and its use for preventing or treating mucositis Pending 16-May-2022
JP-2025518540-A Superoxide dismutase and its use for the prevention or treatment of diabetic retinopathy or uveitis Pending 16-May-2022 A61P31/00
To view HLB Genex’s complete patent history, request access »

HLB Genex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HLB Genex Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore HLB Genex‘s full profile, request access.

Request a free trial

HLB Genex Investments & Acquisitions (4)

HLB Genex’s most recent deal was a Corporate with ACA Next for . The deal was made on 28-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ACA Next 28-May-2025 Corporate Other Commercial Services
Korea Land and Housing (Industrial Complex in Daejeon, South Korea) 25-Apr-2021 Corporate Asset Purchase Buildings and Property
Biobab AiBIO 01-Apr-2019 Corporate Drug Discovery
GF Fermentec 09-Mar-2017 Merger/Acquisition Discovery Tools (Healthcare)
To view HLB Genex’s complete investments and acquisitions history, request access »

HLB Genex ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view HLB Genex’s complete esg history, request access »

HLB Genex Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
GF Fermentec Sejong, South Korea 2000

HLB Genex FAQs

  • When was HLB Genex founded?

    HLB Genex was founded in 2000.

  • Where is HLB Genex headquartered?

    HLB Genex is headquartered in Daejeon, South Korea.

  • What is the size of HLB Genex?

    HLB Genex has 78 total employees.

  • What industry is HLB Genex in?

    HLB Genex’s primary industry is Drug Discovery.

  • Is HLB Genex a private or public company?

    HLB Genex is a Public company.

  • What is HLB Genex’s stock symbol?

    The ticker symbol for HLB Genex is 187420.

  • What is the current stock price of HLB Genex?

    As of 16-Nov-2026 the stock price of HLB Genex is $1.31.

  • What is the current market cap of HLB Genex?

    The current market capitalization of HLB Genex is $42.9M.

  • What is HLB Genex’s current revenue?

    The trailing twelve month revenue for HLB Genex is $32.4M.

  • What is HLB Genex’s annual earnings per share (EPS)?

    HLB Genex’s EPS for 12 months was $0.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process